Detection and molecular characterization of β-lactamase genes in clinical isolates of Gram-negative bacteria in Southern Ecuador  by Delgado, Diana Yessenia Calva et al.
BD
o
G
D
S
a
b
a
A
R
A
A
K


E
G
S
b
t
i
T
o
H
i
d
t
m
h
1
Bbraz j infect dis 2 0 1 6;2  0(6):627–630
www.elsev ier .com/ locate /b j id
The Brazilian Journal of
INFECTIOUS  DISEASES
rief Communication
etection  and  molecular  characterization
f -lactamase  genes  in  clinical  isolates  of
ram-negative bacteria  in Southern  Ecuador
iana Yessenia Calva Delgadoa,1, Zorayda Patricia Toledo Barrigasa,1,
ofía Genoveva Ochoa Astutilloa, Ana Paulina Arévalo Jaramilloa, Alessio Ausili a,b,∗
Universidad Técnica Particular de Loja (UTPL), Departamento de Ciencias de la Salud, Loja, Ecuador
Secretaría Nacional de Educación Superior, Ciencia, Tecnología e Innovación (SENESCYT), Quito, Ecuador
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 7 April 2016
ccepted 12 July 2016
vailable online 30 July 2016
eywords:
-Lactam resistance
-Lactamase
a  b  s  t  r  a  c  t
This work performed a phenotypic and genotypic characterization of 79 clinical isolates of
Enterobacteriaceae and Pseudomonadaceae collected in hospitals of Southern Ecuadorin 2013.
Our  results showed a high incidence of -lactamases and ESBLs with blaTEM and blaCTX-M
as the prevalent genes, respectively. By direct sequencing of PCR amplicons, the differ-
ent  -lactamases and variants of the genes were also distinguished. Our results revealed
a  predominance of TEM-1 -lactamase and the presence of different CTX-M variants with a
prevalence of CTX-M-15. Two infrequent CTX-M variants in South America were also iden-
tiﬁed. To the best of our knowledge, this is one of the ﬁrst studies describing the geneticSBL
enotypic characterization
characteristics of -lactamases in Ecuador.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
(ESBLs), AmpC-type -lactamases, and carbapenemases areince the discovery of antibiotics, many  pathogens which had
een considered defeated have continued to develop resis-
ance to these drugs. The emergence of resistant microorgan-
sms to antibiotics is a problem that has extended globally.1,2
his phenomenon is widespread in hospitals mainly because
f the large and often inappropriate use of antimicrobials.
owever, due to the bacteria’s ability to exchange genetic
nformation, environmental and nosocomial pathogens have
eveloped the same resistance mechanisms, since most resis-
ance genes have their probable origin in environmental
icroorganisms.3 Resistant pathogens to most antibiotics
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Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)have already been described, but in particular it is of great
impact the resistance to -lactams. Resistance to these
antimicrobial agents is due to the production of -lactamases,
and the genes encoding these enzymes have been found
worldwide mainly in Gram-negative bacteria, prevalently in
Enterobacteriaceae and Pseudomonas spp.4,5
Among -lactamases, extended-spectrum -lactamasesof great concern. In particular ESBLs are the most abun-
dant in Enterobacteriaceae,  with more  than 600 natural variants
(http://www.lahey.org/Studies/), and with a prevalence of
lsevier Editora Ltda. This is an open access article under the CC
.
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Table 1 – Resistance rate for the clinical isolates.
Antimicrobial agent-disk concentration Number (%) of resistant isolates
-Lactamase/ESBL (n = 73) AmpC (n = 6) Total (n = 79)
AMK-30 g 9  (11%) 0 (0%) 9 (11%)
AMC-20/10 g 19 (25) 2 (2%) 21 (27%)
AMP-10 g 50 (63%) 1 (1%) 51 (65%)
SAM-10/10 g 47 (59%) 1 (1%) 48 (61%)
ATM-30 g 30 (38) 1 (1%) 31 (39%)
FEP-30 g 13 (16%) 0 (0%) 13 (16%)
CTX-30 g 58 (73%) 0 (0%) 58 (73%)
FOX-30 g 17 (22%) 2 (2%) 19 (24%)
CAZ-30 g 18 (18%) 0 (0%) 18 (23%)
CIP-5 g 52 (66%) 0 (0%) 52 (66%)
IMP-10 g 7 (9%) 0 (0%) 7 (9%)
MEM-10 g 0 (0%) 0 (0%) 0 (0%)
NET-30 g 51 (65%) 1 (1%) 52 (66%)
PTZ-100/10 g 4 (5%) 0 (0%) 4 (5%)
Abbreviations: AMK, amikacin; AMC, amoxicillin/clavulanic acid; AMP, ampicillin; SAM, ampicillin/sulbactam; ATM, aztreonam; FEP,
ciprocefepime; CTX, cefotaxime; FOX, cefoxitin; CAZ, ceftazidime; CIP, 
piperacillin/tazobactam.
CTX-M family that became predominant over TEM and SHV
during the ﬁrst decade of the 21st century.6
As far as we  know, there is a lack of detailed reports char-
acterizing the -lactamase spread in Ecuador.7,8 In this work
a phenotypic and molecular characterization of -lactamases
was performed in clinical pathogens isolated in two main pub-
lic hospitals of the Loja province, Ecuador.
The clinical isolates of Enterobacteriaceae and Pseudomonas
aeruginosa were obtained from patients of Ygnacio Monteros
and IESS Hospitals. The samples were collected between May
and November 2013, while the bacterial cultures were grown
in agar-MacConkey Petri dishes, identiﬁed by traditional bio-
chemical testing and validated by MicrogenTM GnA + B-ID
system.
Antimicrobial susceptibility testing was performed by
Kirby-Bauer disk diffusion procedure according to CLSI
guidelines.9 The isolates were tested for susceptibility to
amikacin (AMK), amoxicillin/clavulanic acid (AMC), ampi-
cillin (AMP), ampicillin/sulbactam (SAM), aztreonam (ATM),
cefepime (FEP), cefotaxime (CTX), cefoxitin (FOX), ceftazidime
(CAZ), ciproﬂoxacin (CIP), imipenem (IMP), meropenem (MEM),
netilmicin (NET), and piperacillin/tazobactam (PTZ). The
investigation of phenotypic production of ESBL and AmpC-
type -lactamase was performed by techniques of double
disk synergism (DDST) on Mueller Hinton agar and com-
bination disk method. In particular for ESBL detection,
DDST was performed on agar with AMC-20/10 g disk pos-
itioned 25 mm (center-to-center) away from disks containing
CAZ-30 g, CTX-30 g, FEP-30 g and ATM-30 g, and the
conﬁrmation combination disk method with disks of CTX-
30 g, cefotaxime/clavulanic acid (30/10 g), CAZ-30 g and
ceftazidime/clavulanic acid (30/10 g)10; for AmpC-type -
lactamase detection, DDST (for constitutive AmpC) was
performed with boronic acid containing disk (30 g) placed at a
center-to-center distance to a CAZ-30 g and a CTX-30 g disk
of 25 mm,  while for combination disk method (for inducible
AmpC), disks of CTX-30 g, CAZ-30 g and ATM-30 g were
placed close to a IMP-10 g.11,12ﬂoxacin; IMP, imipenem; MEM, meropenem; NET, netilmicin; PTZ,
Three multiplex PCR and one simplex PCR were performed
to determine the presence of blaTEM, blaSHV, blaOXA-1-like
and blaCTX-M genes in ESBL-producing isolates, and blaACC,
blaFOX, blaMOX, blaDHA, blaLAT, blaCMY, blaMIR and blaACT genes
in plasmid-mediated AmpC -lactamase-producing isolates.
PCR primers and procedures were performed as previously
described.13
Puriﬁcation and sequencing of PCR products were carried
out by Macrogen Inc. (Korea) and the types of -lactamase
genes were identiﬁed by comparison with the sequences in
GenBank (http://www.ncbi.nlm.nih.gov/genbank/).
During the study, a total of 79 isolates resistant to -lactams
were recovered. The most frequent isolated bacterial species
were Escherichia coli (39) followed by Klebsiella pneumoniae
(9), Klebsiella oxytoca (7) Enterobacter aerogenes (7), Enterobacter
cloacae (5) Proteus mirabilis (3), Pseudomonas aeruginosa (3), Cit-
robacter freundii (3), Proteus vulgaris (2), and Enterobacter koseri
(1).
All isolates showed antimicrobial resistance to one or more
-lactam antibiotics, and among them, 73 were conﬁrmed
to be positive for -lactamase/ESBL and six for AmpC -
lactamase production (see Table 1 for details).
By PCR ampliﬁcation, it was found that 31% of the samples
showed the presence of one -lactamase gene, whilst isolates
often carried two (28%), three (20%), four (18%), and occasion-
ally ﬁve (3%) different variants of -lactamase enzymes (see
Table 2 for details).
The genes encoding CTX-M were the most common and
were found in 63 of the 73 ESBL-producing isolates. In partic-
ular the genes blaCTX-M belonging to phylogenetic groups 1, 2
and 9 were found in 48, 4 and 20 isolates, respectively. It was
also detected that 52 of the ESBL-producing isolates carried
blaTEM, 21 blaSHV, and 34 blaOXA-1-like genes. Finally, blaDHA
was the most frequently observed plasmid-mediated AmpC
-lactamase gene (found in four isolates), while one isolate
carried blaLAT and one blaMOX. To identify the speciﬁc bla genes
detected in the PCR assays, amplicons DNA sequence analyses
were performed and the results are summarized in Table 2.
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Table 2 – Summary of -lactamase encoding genes detected in ESBL-producing bacteria from clinical isolates.
Enzyme Class Family Group Variant Spectrum Combination
-Lactamase (79) -Lactamase (73) CTX-M (72) Group 1 (48) CTX-M-1 (5) Extended
CTX-M-3 (6) Extended
CTX-M-12 (5) Extended
CTX-M-15 (30) Extended BL/ESBL 3/2 (2)
CTX-M-55 (2) Extended BL/ESBL 3/1 (7)
Group 2 (4) CTX-M-2 (4) Extended BL/ESBL 2/2 (8)
Group 9 (20) CTX-M-14 (16) Extended BL/ESBL 2/1 (9)
CTX-M-65 (4) Extended BL/ESBL 1/2 (4)
TEM (52) TEM-1 (51) Broad BL/ESBL 1/1 (20)
TEM-12 (1) Extended BL 3 (2)
SHV (21) SHV-1 (5) Broad BL 2 (2)
SHV-2 (4) Extended BL 1 (3)
SHV-11 (10) Broad ESBL 1 (16)
SHV-12 (2) Extended AmpC (6)
OXA-1-like (34) *OXA-1-like (34) Broad
AmpC (6) DHA  (4) DHA-1 (4) Broad
LAT (1) CMY-75 (1) Broad
MOX (1) MOX (1) Broad
The numbers in brackets represent the number of isolates (in enzyme and class columns) and of found genes (in family, group, variant and
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of blaOXA-1-like, it was not possible to distinguish the different varian
Many  studies on the resistance to -lactams conducted in
outh America were performed using mainly a phenotypic
pproach. In Ecuador the few reports published on this topic
ack almost totally of a genotypic study,14–17 and, to the best
f our knowledge, this is one of the ﬁrst studies describing the
enetic characteristics of -lactamases in this country.8,9,17
Our data conﬁrmed the prevalence in Loja province of E. coli
nd Klebsiella spp. as -lactamase producers,6,18 and a pre-
ominance of ESBL producers, showing the highest resistance
evels mainly against cefotaxime, ciproﬂoxacin, netilmicin,
nd ampicillin.
It is widely documented that in South America ESBL-
roducing Enterobacteriaceae have one of the highest incidence
n the world and CTX-Ms are the most broadly distributed.9
n particular the type CTX-M-2 is the most frequent in the
outhern Cone,19 CTX-M-2-group, CTX-M-8, and CTX-M-9 in
razil,20 CTX-M-1-group in Colombia,21 and CTX-M-2, CTX-M-
4, CTX-M-15, CTX-M-24, and CTX-M-56 in Peru and Bolivia.22
In our study, it is documented that CTX-M enzymes are
he dominant ESBLs in the Loja province, and among them
he prevailing types are CTX-M-15 and CTX-M-14. These
ata are consistent with the literature21,22 as these two vari-
nts are present and quite frequent in Ecuador neighboring
ountries. Interestingly, the types CTX-M-55 and CTX-M-65
ere detected. Actually, these variants are common in East
sia,23,24 and one possible hypothesis of their presence in
outhern Ecuador can be related to the recent immigra-
ion from China and the trade relationship between Ecuador
nd China.25 As expected, a strong presence of TEM-type -
actamases was also found, in particular TEM-1 -lactamase.
EM-type presents a wide geographical distribution, and in
cuador these data are not particularly surprising consider-
ng the incidence of TEM in neighboring Colombia26 and the
rade and migratory ﬂows between these two countries, as
ell as the recent intense Ecuadorian immigration to and from
urope and North America where TEM is predominant suchtions of -lactamase (BL), ESBL and AmpC genes found. *In the case
 direct sequencing of PCR amplicons.13
as CTX-M-15. It is worth to mention the ﬁnding of one iso-
late harboring TEM-12. This ESBL variant has been already
found in South America27 and it is one of the most com-
mon in North America.28 In our study, the presence of the
non-ESBL OXA-1-type, SHV-1 and SHV-11, mainly found in
Klebsiella (9 isolates) and Proteus (4 isolates), and the ESBL
SHV-2 and SHV-12, found in Enterobacter, Klebsiella and E. coli,
were also detected. The non-ESBL OXA-1-type and SHV-1
are among the most widespread in Enterobacteriaceae,29 while
to the best of our knowledge SHV-11 variant is emergent
in South America. Regarding ESBLs, the variants found in
this study are among the most common in Latin Amer-
ica, indeed SHV-2 with SHV-5 were the ﬁrst ESBL SHV-types
described in Enterobacteriaceae,30 while SHV-12 is highly preva-
lent in Mexico, Colombia, and Brazil.31 Concerning AmpC
-lactamase, there is not sufﬁcient data to draw signiﬁcant
conclusions on its epidemiology, but it is interesting to note
the presence of two CMY-75 genes found in C. freundii. This
variant has been already detected in C. freundii in Spain
(EMBL/GenBank/DDBJ databases: AFK73434.1), but is emergent
in South America. On the other hand DHA-1 has been previ-
ously recognized in South America, being quite predominant
in Argentina.32
In conclusion, in this work the predominance of ESBLs
in Southern Ecuador was demonstrated with a prevalence
of CTX-M-type enzymes and we identiﬁed two emergent
variants in South America. A high presence of TEM-type -
lactamases were also detected, being TEM-1 -lactamase the
most frequent variant found. However, there are some lim-
itations in this study, including the low number of isolates
and the restricted geographical area of sampling. In order to
minimize these problems and gather more  indicative informa-
tion on molecular epidemiology and genetic characteristics
of -lactamases within the entire territory of Ecuador, fur-
ther isolates from different health institutions and regions of
Ecuador have to be collected and characterized.
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